FGF21 and fatty liver disease: The PCB126 exposure induced various manifestations of hepatic steatosis (Figure 1B–F), including liver volume and weight gain (Figure S1C,D), increased vacuolization/lipid accumulation (Figure 1B,C), hepatic TG (Figure 1D), hepatic FFA (Figure 1E) and elevated plasma levels of native FGF21 (Figure 1F) in mice fed a SD or HFD.